Aldea Pharmaceuticals, a biotechnology startup developing an emergency treatment for alcohol poisoning, seemed like an attractive investment to venture capitalist David Coats. But he didn’t rely on a hunch—he consulted the computer model he’d built.
Two weeks and a few phone calls later, he cut the company a $1.25 million check. “A decision like that would have normally taken a minimum of three months,” says Tim Shannon, a partner with Canaan Partners, the firm that had led Aldea’s $7 million fund-raising round.
The $1.25 million was a follow-on investment from Correlation Ventures, which calls itself a “new breed of venture capital firm”—one driven by predictive analytics software built over the last six years by founder Coats and his partner Trevor Kienzle. The effort adds efficiency to the investment process. And for entrepreneurs, it means far faster answers: rejections come in as little time as two days.
To run its model, Correlation Ventures, which is based in San Diego and Palo Alto, California, asks startups to submit five basic planning, financial, and legal documents. It enters these into a program similar in function to credit rating software.
A top-ranked score leads to a 30-minute interview with both the startup CEO and the outside venture firm leading the investment, plus a quick legal review and background check. As a co-investor, Correlation Ventures always relies on some vetting by the primary investor.
Correlation Ventures will then often deliver a check from its $165 million fund, closed last November, in less than two weeks. “That’s unheard of in the venture industry,” says Coats.
Once it makes an investment, Correlation backs off and doesn’t take a board seat. That policy is itself data driven: the firm’s analytics show that companies with more than two VCs on the board are less likely to be successful.
What’s not yet clear is whether this system works. Correlation Ventures has so far invested in 26 companies in diverse sectors but says it is too early to report successes or failures.
None of this might have been possible a decade ago. Harvard Business School professor Matthew Rhodes-Kropf, who advises Correlation Ventures and is now an investor in the fund, says the venture capital industry has only recently worked through enough business cycles to look for subtle trends.
There was also no complete, accurate, public set of venture capital data, so Correlation Ventures hustled for it. To build and maintain its database, it partnered with Dow Jones, scoured the Internet, signed nondisclosure agreements with more than 20 venture funds to see their internal statistics, and called hundreds of companies.
While so-called Big Data companies have attracted plenty of investors, the reputation-driven venture capital industry itself has yet to embrace their tools. (There are exceptions, such as Google Ventures, which uses quantitative analysis to help guide decisions.)
Rhodes-Kropf says venture capitalists are good at identifying companies that will have the best chances at success but not as good at predicting which will be the next Facebook. And one finding from Coats’s research is that while top-tier firms do invest in a disproportionate share of “winning” companies, the majority of successful investments are led by firms that don’t even crack the top 50. So it makes logical sense for Correlation Ventures to focus equal time and energy on many companies and co-invest with a diverse set of venture capital firms, he says.
To explain his project, Coats cites Moneyball, the book and movie about how Oakland Athletics general manager Billy Beane rejected the conventional wisdom on evaluating baseball players and built a winning franchise by letting a computer tease out variables that others overlooked. He believes the averages will work out. “We’re not claiming to have a magic crystal ball,” he says. “We’re tilting the odds a little in our favor with each investment.”
These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
Why China is still obsessed with disinfecting everything
Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
A quick guide to the most important AI law you’ve never heard of
The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.